Drugs / Etoricoxib
Etoricoxib
also known as
MK0663 · Arcoxia · Algix · Drug: Arcoxia · ETOR · Etoricoxib, Arcoxia · etoricoxibe · ETOX · +2 more
Small molecule targets PTGS2 via inhibition
Trials 67 · started per year
today
1
2
3
4
6
3
4
2
8
5
6
5
4
4
1
1
1
2
2
2
1
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05142098 | Jan → Jul 2022 | — | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07454369 | Oct → Nov 2022 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT02503839 | Nov 2015 → Sep 2019 | tuberculosis | Anne Margarita Dyrhol Riise | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01980940 | Dec 2013 → Nov 2014 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 1/2 | NCT01614301 | May 2012 → May 2014 | melanoma | University of Regensburg | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05995912 | Sep 2021 → Aug 2022 | — | Laboratorios Liomont | Completed | No outcome recorded |
| Phase 2 | NCT04565600 | Mar 2020 → Apr 2021 | neurological pain disorder | Guangdong Provincial People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01619150 | Jul 2012 → Jul 2013 | osteoarthritis | C4Pain | Completed | No outcome recorded |
| Phase 2 | NCT00746720 | May 2006 → Jul 2009 | osteoarthritis, hip | University of Erlangen-Nürnberg Medical School | Terminated | No outcome recorded |
| Phase 2 | NCT00264147 | Jan 2006 → Mar 2008 | rheumatoid arthritis | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT00095017 | Nov 2004 → ? | bone neoplasm | Organon and Co | Withdrawn | No outcome recorded |
| Phase 2 | NCT00242489 | Jun 1998 → Feb 1999 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT05683574 | May 2026 → Oct 2027 | — | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07549386 | May 2024 → Mar 2025 | osteoarthritis | Laboratorios Liomont | Completed | No outcome recorded |
| Phase 3 | NCT04968158 | Nov 2021 → Mar 2022 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT01979510 | Nov 2013 → May 2014 | — | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT02438709 | Dec 2012 → Jul 2015 | primary hypertrophic osteoarthropathy | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01554163 | Mar 2012 → Mar 2013 | osteoarthritis, knee | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01462370 | Nov 2011 → Jun 2012 | primary dysmenorrhea | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01229774 | Feb 2011 → Aug 2014 | osteoarthritis, hip | University of Regensburg | Completed | No outcome recorded |
| Phase 3 | NCT01208181 | Sep 2010 → Jun 2014 | rheumatoid arthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01208207 | Sep 2010 → Nov 2014 | ankylosing spondylitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01091675 | Sep 2010 → May 2013 | ankylosing spondylitis | Spanish Foundation of Rheumatology | Completed | No outcome recorded |
| Phase 3 | NCT00820027 | Dec 2008 → Dec 2010 | neuropathy, painful | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00788710 | Oct 2008 → Jul 2010 | acute female pelvic peritonitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00756873 | Oct 2008 → Sep 2009 | — | University of Regensburg | Unknown | No outcome recorded |
| Phase 3 | NCT00694369 | Jun → Dec 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01017380 | Jan 2008 → Jan 2009 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 3 | NCT00373464 | Mar 2006 → Mar 2007 | — | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00149253 | Dec 2004 → May 2005 | — | Khon Kaen University | Completed | No outcome recorded |
| Phase 3 | NCT00092781 | Mar 2004 → Feb 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092768 | Mar 2004 → Feb 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092755 | Apr → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00269191 | Feb → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092742 | Feb 2003 → Dec 2005 | rheumatoid arthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00250445 | Jan 2003 → May 2006 | arthritic joint disease | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092703 | Jun 2002 → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092729 | Jun → Dec 2002 | primary dysmenorrhea | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00542087 | Mar → Dec 2002 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00393211 | Apr → Nov 2000 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00393354 | Apr → Nov 2000 | — | Organon and Co | Completed | No outcome recorded |
| Phase 423 trials | ||||||
| Phase 4 | NCT06401499 | Jun → Oct 2024 | — | Muhammad Ilyas | Unknown | No outcome recorded |
| Phase 4 | NCT02149758 | Jan → Jun 2013 | chronic periodontitis | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
| Phase 4 | NCT02568735 | Jan 2013 → Dec 2014 | neuropathy, painful | Kuopio University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01429168 | Oct 2011 → Aug 2012 | osteoarthritis | Organon and Co | Withdrawn | No outcome recorded |
| Phase 4 | NCT01259830 | Mar 2011 → Apr 2014 | — | Claudia Spies | Terminated | No outcome recorded |
| Phase 4 | NCT01264237 | Mar → Aug 2011 | postherpetic neuralgia | Analgesic Solutions | Unknown | No outcome recorded |
| Phase 4 | NCT01190722 | Nov → Dec 2010 | toe, misshapen | Karolinska Institutet | Withdrawn | No outcome recorded |
| Phase 4 | NCT00927004 | Aug 2010 → Nov 2011 | osteoarthritis | Curtin University | Completed | No outcome recorded |
| Phase 4 | NCT01148303 | Jul → Aug 2010 | headache disorder | Hartford Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01022190 | Dec 2009 → Oct 2011 | myositis ossificans | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00954785 | Nov 2009 → Dec 2010 | — | University of Cape Town | Withdrawn | No outcome recorded |
| Phase 4 | NCT00792376 | Aug 2009 → Dec 2011 | disease of the tendon | Argentine Tennis Association | Completed | No outcome recorded |
| Phase 4 | NCT00855777 | Apr → Dec 2009 | — | University of Verona | Unknown | No outcome recorded |
| Phase 4 | NCT00733421 | Oct 2008 → Jun 2009 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT00755521 | Sep 2008 → Oct 2010 | fibromyalgia | Meir Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00757627 | Dec 2007 → Dec 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT04144101 | Mar → Jul 2007 | rheumatoid arthritis | Chung Shan Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00565682 | Apr → Dec 2006 | cholecystitis, ovarian cyst | Hospital Vozandez | Completed | No outcome recorded |
| Phase 4 | NCT00380627 | Sep 2005 → Jan 2006 | — | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00380523 | Apr → May 2005 | — | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00142558 | Jan → May 2005 | gout | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00140972 | Dec 2004 → Jun 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00090181 | Jun 2004 → Mar 2005 | chronic pain syndrome | Organon and Co | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02534610 | Jan → Aug 2014 | — | Foisor Orthopedics Clinical Hospital | Completed | No outcome recorded |
| — | NCT01002690 | Oct 2009 → Apr 2012 | asthma | Barbro Dahlen | Completed | No outcome recorded |
| — | NCT00793052 | Nov 2008 → Dec 2009 | congenital temporomandibular joint ankylosis | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 43 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07559682 Comparator | May → Aug 2025 overdue | — | Sharif Medical Research Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05533073 Comparator | Aug → Sep 2020 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT01304069 Comparator | Jan → Jul 2011 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01271348 Comparator | Jan → Oct 2011 | — | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07370532 Comparator | Jan 2026 → Nov 2027 expected | Parkinson disease | Ihab Elsayed Hassan | Recruiting | No outcome recorded |
| Phase 2 | NCT04462666 Comparator | Jul 2020 → Jul 2023 | gout | Shanghai Yueyang Integrated Medicine Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01246362 Comparator | Jul 2011 → Jan 2014 | osteoarthritis, knee | Singapore General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01088256 Comparator | Feb 2011 → Aug 2012 | complex regional pain syndrome type 2, peripheral nerve lesion, polyneuropathy, postherpetic neuralgia +1 | Ruhr University of Bochum | Terminated | No outcome recorded |
| Phase 2 | NCT01269515 Comparator | Oct 2010 → Nov 2014 | HIV infectious disease | Dag Kvale | Completed | No outcome recorded |
| Phase 2 | NCT02456363 Background | Nov 2009 → Oct 2019 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT00427999 Background | Feb 2007 → Jun 2015 | prostate cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07328022 Comparator | May → Aug 2025 | bursitis, synovitis, tendinitis | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT06863701 Comparator | Jan 2025 → Dec 2026 expected | gout | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06863662 Comparator | Sep 2024 → Sep 2025 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT06517823 Comparator | Apr → Oct 2024 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT03011905 Background | Jan 2017 → Apr 2019 | neuropathy, painful | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02954484 Comparator | Apr 2015 → May 2017 | neuropathy, painful | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 3 | NCT02750917 Comparator | Sep 2014 → Jan 2015 | — | Foisor Orthopedics Clinical Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00876317 Comparator | Nov 2009 → Nov 2010 | tenosynovitis | Clinica Virgen Milagrosa | Terminated | No outcome recorded |
| Phase 3 | NCT00716833 Comparator | Feb 2006 → Dec 2010 | — | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT07661030 Background | Jul 2026 → Jul 2027 expected | gout | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06791434 Background | Aug 2024 → Aug 2025 | — | Dr. Vishwanath Karad MIT World Peace University | Completed | No outcome recorded |
| Phase 4 | NCT05791721 Comparator | Oct 2021 → Dec 2022 | — | University of Belgrade | Completed | No outcome recorded |
| Phase 4 | NCT03582332 Comparator | Jan → Jun 2016 | spondyloarthropathy | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT01344720 Comparator | May 2011 | — | Azienda Sanitaria Locale 4, Teramo | Unknown | No outcome recorded |
| Phase 4 | NCT00763685 Comparator | Jun 2010 → Nov 2011 | — | East Tallinn Central Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01067430 Comparator | Apr → Oct 2010 | rheumatoid arthritis | Northumbria Healthcare NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 4 | NCT00935116 Comparator | Jul 2009 → Sep 2010 | — | Hospital Padre Hurtado | Unknown | No outcome recorded |
| Phase 4 | NCT00525993 Comparator | Dec 2008 → Aug 2009 | — | Núcleo de Estudos em Esportes e Ortopedia, Brazil | Unknown | No outcome recorded |
| Phase 4 | NCT00752921 Comparator | Sep → Oct 2008 | headache disorder | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00554346 Comparator | May 2008 → Jun 2010 | — | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00799149 Comparator | Jun 2006 → May 2007 | — | Meir Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00440739 Comparator | Sep 2005 → Dec 2007 | — | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT01361789 Comparator | Jan 2004 → Dec 2009 | — | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT06001112 Comparator | Sep → Dec 2023 | gout | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT05256342 Comparator | Dec 2021 → Apr 2024 | osteoarthritis, knee | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT04883034 Comparator | Jun 2020 → Jun 2021 | — | Gadjah Mada University | Unknown | No outcome recorded |
| — | NCT03542955 Comparator | May 2018 → Jul 2019 | spondylosis, cervical | BioElectronics Corporation | Completed | No outcome recorded |
| — | NCT03117894 Comparator | May 2017 → Oct 2020 | breast cancer | Umeå University | Completed | No outcome recorded |
| — | NCT02884986 Comparator | Jan 2015 | — | Bnai Zion Medical Center | Completed | No outcome recorded |
| — | NCT01638962 Comparator | Aug 2012 → Aug 2015 | osteoarthritis, knee | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT01300780 Comparator | Apr 2010 → Sep 2011 | — | Eloisa Andrade de Paula | Completed | No outcome recorded |
| — | NCT00529594 Comparator | Aug → Nov 2006 | proliferative diabetic retinopathy | University of Sao Paulo | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 112 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etoricoxib | “Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg” NCT06791434 ↗105“MK-0663B (etoricoxib 90 mg immediate release” NCT01979510 ↗ “Etoricoxib” NCT01638962 ↗ “EtoriCoxib” NCT02438709 ↗ |
| Known as | Algix | “Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a new COX-2 selective inhibitor” NCT00716833 ↗ |
| Known as | Arcoxia | “The purpose of the study is evaluate the analgesic efficacy and safety profile of the Cox-2 specific analgesic Etoricoxib (arcoxia®) when administrated pre and postoperatively...” NCT00935116 ↗16“We therefore propose to conduct a second study using etoricoxib (Arcoxia) - a Cox 2 specific antiinflammatory medication with a longer half life than rofecoxib.” NCT00752921 ↗ “participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil).” NCT01300780 ↗ “Etoricoxib (Arcoxia®) is a NSAID with anti-inflammatory and analgesic properties mainly achieved via selective peripheral COX-2 inhibition.” NCT02884986 ↗ “This possible reduction of blood loss during pain management with Etoricoxib (Arcoxia) will be investigated the described clinical trial.” NCT01229774 ↗ “Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a new COX-2 selective inhibitor” NCT00716833 ↗ “A2: Etoricoxib (Arcoxia®, Laboratorios Schering-Plough, S.A. de C.V.)” NCT07454369 ↗ “Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery” NCT01361789 ↗ “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days” NCT00380627 ↗ “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days” NCT00380523 ↗ “Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+” NCT01614301 ↗ “Etoricoxib 120mg is Arcoxia 120mg” NCT00529594 ↗ “Arcoxia(etoricoxib 90 mg/tablet)” NCT00554346 ↗ “etoricoxib 90 mg (Arcoxia®)” NCT05683574 ↗ “Drug: Arcoxia” NCT02456363 ↗ |
| Known as | Drug: Arcoxia | “Drug: Arcoxia” NCT02456363 ↗ |
| Known as | ETOR | “etoricoxib (ETOR) 4% dimethyl sulfoxide (DMSO) and propylene glycol (PG) formulations” NCT01980940 ↗ |
| Known as | Etoricoxib, Arcoxia | “Etoricoxib, Arcoxia” NCT01022190 ↗ |
| Known as | etoricoxibe | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04883034 ↗ |
| Known as | ETOX | “Analgesic efficacy of etoricoxib (ETOX), a high selective COX-2 inhibitor has been shown as superior compared to placebo and other nonsteroidal anti-inflammatory drugs in third...” NCT05791721 ↗ |
| Known as | L-791456 | ChEMBL registry synonym — accepted as the source's own label CHEMBL416146 ↗ |
| Known as | MK0663 | “A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120...” NCT00694369 ↗18“MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)” NCT00242489 ↗ “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days” NCT00380523 ↗ “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days” NCT00380627 ↗ “MK0663, Etoricoxib / Duration of Treatment : 12 Weeks” NCT00393354 ↗ “MK0663, Etoricoxib / Duration of Treatment : 12 Weeks” NCT00393211 ↗ “MK0663, etoricoxib / Duration of Treatment: 6 Weeks” NCT00542087 ↗ “120 mg of etoricoxib (MK0663) for a total of 5 days” NCT00788710 ↗ “MK0663, etoricoxib / Duration of Treatment: 4 weeks” NCT00095017 ↗ “MK0663, etoricoxib / Duration of Treatment: 4 weeks” NCT00090181 ↗ “MK0663, etoricoxib / Duration of Treatment 12 Weeks” NCT00269191 ↗ “MK0663; etoricoxib / Duration of Treatment: 5 Days” NCT00142558 ↗ “MK0663; etoricoxib / Duration of Treatment:4 Weeks” NCT00140972 ↗ “MK0663, etoricoxib” NCT00092768 ↗ “MK0663, etoricoxib” NCT00092742 ↗ “MK0663, etoricoxib” NCT00092755 ↗ “MK0663, etoricoxib” NCT00250445 ↗ “MK0663, etoricoxib” NCT00092781 ↗ “MK0663, etoricoxib” NCT00092703 ↗ |
| Known as | Tauxib | “Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a new COX-2 selective inhibitor” NCT00716833 ↗ |
| Action | Inhibit | “etoricoxib, a COX-2 selective inhibitor” PMID 16321158 ↗ Dec 2005 |
| Modality | Small molecule | “It is a potent, oral coxib; thus cheaper and more simple than IV NSAIDs.” NCT00373464 ↗ |
| Route | Oral | “single dose (orally) of etoricoxib 120 mg” NCT00149253 ↗ |
| Target | PTGS2 | “Analgesic efficacy of etoricoxib (ETOX), a high selective COX-2 inhibitor has been shown as superior compared to placebo and other nonsteroidal anti-inflammatory drugs in third...” NCT05791721 ↗ |